EP1603587A1 - Marqueurs endotheliaux 1, 9 et 17 e tumeur favorisant l'angiogenese - Google Patents

Marqueurs endotheliaux 1, 9 et 17 e tumeur favorisant l'angiogenese

Info

Publication number
EP1603587A1
EP1603587A1 EP04717465A EP04717465A EP1603587A1 EP 1603587 A1 EP1603587 A1 EP 1603587A1 EP 04717465 A EP04717465 A EP 04717465A EP 04717465 A EP04717465 A EP 04717465A EP 1603587 A1 EP1603587 A1 EP 1603587A1
Authority
EP
European Patent Office
Prior art keywords
tem
vector
protein
biologically active
endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04717465A
Other languages
German (de)
English (en)
Inventor
Beverly Teicher
Bruce Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP1603587A1 publication Critical patent/EP1603587A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Abstract

L'invention concerne des procédés et des compositions favorisant l'angiogenèse par expression exogène de protéine de marqueur endothélial de tumeur (TEM) 1, TEM 9, ou TEM 17, ou de fragments biologiquement actifs correspondants, dans les cellules endothéliales. L'invention concerne également des procédés permettant d'identifier l'angiogenèse dans des souris transgéniques pour les protéines TEM 1, TEM 9, ou TEM 17. Il s'agit donc de procédés et de compositions utiles pour accélérer ou renforcer la guérison des blessures, le traitement des tissus anoxiques (par exemple muscle cardiaque), les ulcères et les tissus transplantés, en particulier les greffes vasculaires, dans les vertèbres.
EP04717465A 2003-03-04 2004-03-04 Marqueurs endotheliaux 1, 9 et 17 e tumeur favorisant l'angiogenese Withdrawn EP1603587A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US45185603P 2003-03-04 2003-03-04
US45185203P 2003-03-04 2003-03-04
US451856P 2003-03-04
US451852P 2003-03-04
US45246903P 2003-03-06 2003-03-06
US452469P 2003-03-06
US46379903P 2003-04-18 2003-04-18
US463799P 2003-04-18
PCT/US2004/006731 WO2004078192A1 (fr) 2003-03-04 2004-03-04 Marqueurs endotheliaux 1, 9 et 17 e tumeur favorisant l'angiogenese

Publications (1)

Publication Number Publication Date
EP1603587A1 true EP1603587A1 (fr) 2005-12-14

Family

ID=32966711

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04717465A Withdrawn EP1603587A1 (fr) 2003-03-04 2004-03-04 Marqueurs endotheliaux 1, 9 et 17 e tumeur favorisant l'angiogenese

Country Status (3)

Country Link
EP (1) EP1603587A1 (fr)
JP (1) JP2006519873A (fr)
WO (1) WO2004078192A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3025354A1 (fr) 2006-11-09 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Expression de gene differentielle dans une angiogenese physiologique et pathologique
US10471122B2 (en) * 2015-07-31 2019-11-12 Blue Blood Biotech Corp. Composition for use in promoting wound healing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307557A2 (fr) * 2000-08-02 2003-05-07 The Johns Hopkins University Profils d'expression de cellules endotheliales

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004078192A1 *

Also Published As

Publication number Publication date
WO2004078192A1 (fr) 2004-09-16
JP2006519873A (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
Wang et al. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat
CA2311643C (fr) Compositions et procedes induisant l'expression genique
AU2004257485B2 (en) Methods and pharmaceutical compositions for healing wounds
CZ298488B6 (cs) Farmaceutický prostredek s obsahem tumor-supresorové nukleové kyseliny
CA2408228A1 (fr) Procede servant a favoriser la neovascularisation
KR20010093804A (ko) 심근증 유전자 치료
EA005157B1 (ru) Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов
KR20010108053A (ko) 당뇨병성 허혈성 질환 유전자 치료
KR20120023633A (ko) 허혈 및 당뇨병 상처 치유를 촉진하기 위한 조성물, 키트 및 방법
US20030228283A1 (en) Preventing secondary lymphedema with VEGF-D DNA
US7074399B2 (en) Treatment of inflammation with p20
Shim et al. Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model
NZ573737A (en) Methods and pharmaceutical compositions for healing wounds comprising a PKC modulator
US6468960B1 (en) Therapeutic compositions and methods for enhancing angiogenesis
EP1603587A1 (fr) Marqueurs endotheliaux 1, 9 et 17 e tumeur favorisant l'angiogenese
WO2019027299A2 (fr) Composition pharmaceutique pour la prévention ou le traitement de troubles vasculaires comprenant une cellule souche mésenchymateuse exprimant un facteur de croissance des hépatocytes en tant que principe actif
US20090305977A1 (en) Method for treating peripheral arterial disease with zinc finger proteins
US20030148952A1 (en) Methods and materials for the recruitment of endothelial cells
AU2011226776B2 (en) Methods and pharmaceutical compositions for healing wounds
US7309606B2 (en) Methods and compositions for treating hypercholesterolemia
US10870690B2 (en) Protein therapeutant and method for treating cancer
CN101391105A (zh) 以野生型或突变型eNOS对重症肢体缺血的基因治疗
US20050032687A1 (en) Method and composition for the modulation of angiogenesis
JP4583763B2 (ja) 切断型２４ｋＤａ塩基性線維芽細胞成長因子
US20090233848A1 (en) Pea15 as a Tumor Suppressor Gene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071002